Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California-based genomics development company Exelixis has submitted an application to the FDA to advance XL184, a compound found to be effective in the prevention of tumor growth.
Subscribe to our email newsletter
XL184 is the seventh drug to reach clinical development from the company’s internal discovery program within two years. Pending FDA clearance, Exelixis intends to initiate a phase I clinical trial of the formulation.
In preclinical studies, XL184 has shown potent inhibition of the hepatocyte growth factor receptor (Met) and vascular endothelial growth factor receptor 2 (VEGFR2 [KDR]) receptor tyrosine kinases (RTKs), proteins, which are believed to play synergistic roles in promoting tumor growth and angiogenesis.
Additionally, XL184 has exhibited potent inhibition of other important RTKs that have been implicated in various forms of cancer including mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (Flt3) and tyrosine-protein kinase receptor (Tie-2). In preclinical efficacy studies, XL184 prevented tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma.
The company currently has ongoing phase I clinical trials for a number of other compounds and expects to initiate phase II and III studies by the end of the year.